There was a negligible increase in survival in almost all carriers of the pathogenic variants of BRCA1 and BRCA2 with TN breast cancer in stage II who underwent any secondary risk–reducing strategy compared with surveillance. This evidence concerns the gene BRCA2 and breast cancer.